New agents and perspectives in the pharmacological treatment of major depressive disorder
Authors:
- Marsal SanchesMSMarsal Sanches
- Joao QuevedoJQJoao Quevedo
- 1 March 2021
- journal article
- review article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 106, 110157
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Health/National Institute of Mental Health (1R21MH117636-01A1)
- John S. Dunn Foundation
- Anne and Don Fizer Foundation
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina
- Instituto Cérebro e Mente
This publication has 89 references indexed in Scilit:
- The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical PracticeInternational Journal of Molecular Sciences, 2013
- Brain-Derived Neurotrophic Factor and Neuropsychiatric DisordersPharmacological Reviews, 2012
- Major depressive disorder: new clinical, neurobiological, and treatment perspectivesThe Lancet, 2012
- Cysteamine Attenuates the Decreases in TrkB Protein Levels and the Anxiety/Depression-Like Behaviors in Mice Induced by Corticosterone TreatmentPLOS ONE, 2011
- Efficacy and Safety of Mifepristone for the Treatment of Psychotic DepressionJournal of Clinical Psychopharmacology, 2011
- The GABAergic deficit hypothesis of major depressive disorderMolecular Psychiatry, 2010
- Emerging drugs for bipolar disorderExpert Opinion on Emerging Drugs, 2010
- Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNFNeurobiology of Disease, 2010
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLOS Medicine, 2006
- Substance P antagonists: novel agents in the treatment of depressionExpert Opinion on Investigational Drugs, 2000